Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 21, 2024 08:00 ET | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...
February 08, 2024 08:00 ET | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine

Resmetirom is the first investigational medicine for NASH to achieve fibrosis improvement and NASH resolution primary endpoints in a Phase 3 trialDetailed analyses reinforce the safety profile of...
February 06, 2024 16:05 ET | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...
January 29, 2024 08:00 ET | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Announces Additions to Its Leadership Team

CONSHOHOCKEN, Pa., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...
January 22, 2024 08:00 ET | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...
January 04, 2024 08:00 ET | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Presents Five Health Economics Outcomes Research Abstracts at the NASH-TAG Annual Conference

Abstracts highlight the serious clinical burden of uncontrolled NASH and identify opportunities to improve patient careIn an analysis of patient records from a large claims database, the risk of...
January 03, 2024 16:30 ET | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

CONSHOHOCKEN, Pa., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...
December 22, 2023 16:30 ET | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., Dec. 22, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...
November 27, 2023 16:30 ET | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...
November 21, 2023 08:00 ET | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Appoints Ronald Filippo as Chief Information Officer

CONSHOHOCKEN, Pa., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right